Bayer AG (FRA:BAYN) has been given a €121.00 ($144.05) target price by equities research analysts at Warburg Research in a research note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the healthcare company’s stock.
A number of other brokerages also recently issued reports on BAYN. Independent Research GmbH set a €120.00 ($142.86) price target on Bayer AG and gave the company a “neutral” rating in a report on Thursday, July 27th. Deutsche Bank AG set a €124.00 ($147.62) price target on Bayer AG and gave the company a “buy” rating in a report on Monday, August 28th. UBS AG set a €125.00 ($148.81) price target on Bayer AG and gave the company a “buy” rating in a report on Tuesday, June 27th. Kepler Capital Markets set a €102.00 ($121.43) price target on Bayer AG and gave the company a “neutral” rating in a report on Monday, August 28th. Finally, Nord/LB set a €106.00 ($126.19) price target on Bayer AG and gave the company a “neutral” rating in a report on Friday, July 28th. Eight analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Bayer AG has an average rating of “Buy” and an average target price of €120.23 ($143.13).
Bayer AG (BAYN) opened at 110.075 on Wednesday. The company has a 50 day moving average of €108.12 and a 200 day moving average of €111.37. Bayer AG has a 12 month low of €85.72 and a 12 month high of €123.83. The stock has a market capitalization of €96.00 billion and a price-to-earnings ratio of 19.041.
WARNING: “Bayer AG (BAYN) PT Set at €121.00 by Warburg Research” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://sportsperspectives.com/2017/09/22/bayer-ag-bayn-pt-set-at-121-00-by-warburg-research.html.
Bayer AG Company Profile
Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.